Yüklüyor......
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), w...
Kaydedildi:
| Yayımlandı: | J Hematol Oncol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4782349/ https://ncbi.nlm.nih.gov/pubmed/26951079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0251-8 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|